EBPC(NSC229530) , 98% , 4450-98-0

CAS NO.：4450-98-0

Empirical Formula: C14H15NO4

Molecular Weight: 261.27

MDL number: MFCD00179167

PRODUCT Properties

• Melting point: 135-136 °C
• Boiling point: 479.8±45.0 °C(Predicted)
• Density: 1.340±0.06 g/cm3(Predicted)
• storage temp.: room temp
• solubility: DMSO: ≥10mg/mL
• form: white powder
• pka: 4.50±1.00(Predicted)

Description and Uses

The human aldose reductase AKR1B1 is considered the rate limiting enzyme of the polyol pathway responsible for the conversion of glucose into sorbitol. It also acts as a highly efficient PGF_2α synthase in response to interleukin-1β. Increased aldose reductase expression has been associated with complications of diabetes and may contribute to reduced efficacy of certain chemotherapeutic drugs. EBPC is a potent, selective inhibitor of aldose reductase with an IC₅₀ value of 47 nM in vitro. Through its regulation of glucose metabolism, EBPC has been used to improve the cytotoxic effects of the anticancer agents doxorubicin and cisplatin in HeLa cervical carcinoma cells. EBPC also inhibits prostaglandin F_2α (PGF_2α) and PGE₂ production in human endometrial cells with an EC₅₀ value of 10 μM.

A highly specific aldose reductase inhibitor that has been shown to enhance HeLa cell sensitivity to chemotherapeutic drugs.

Safety

• Symbol(GHS): GHS05,GHS07
• Signal word: Danger
• Hazard statements: H302-H318
• Precautionary statements: P280-P305+P351+P338
• Hazard Codes: Xn
• Risk Statements: 22-41
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT